baber/WOPTO huggingface dataset:
Patent NZ-504120-A (NZ)
Title: Backup pad for rotary grinder comprises compressible pad with gaps joined to a support
Inventor: KNOWLTON GLENN R
IPC: B24D9/08
Filed: 2000-04-19
Abstract: A backup pad for an abrasive disk comprises a circular compressible pad 1 having a first surface adapted for attachment to an abrasive disk and a second surface laminated to a relatively rigid support member 4 with an axially amounted means 7 for attachment to a rotary grinder.  Circular compressible pad 1 is provided with from three to six gaps 2 in its circumference space around the circumference of the pad, penetrating from 10 to 50% of the radius of the pad.  Relatively rigid support member 4 has a similar shape and dimensions to compressible pad 1 except that a segment 5 is removed from at least a portion of the circumference of support member 4 between gaps 2 such that pad 1 extends radially beyond support member 4 in the vicinity of such removed segments 5.
Patent NZ-505584-A (NZ)
Title: Delivery of a therapeutic agent to the smooth muscle cells of a body passageway via an adventia
Inventor: HUNTER WILLIAM L
IPC: A61K33/24
Filed: 1997-05-26
Abstract: Methods for treating or preventing diseases associated with body passageways are described.  The methods comprise delivering a therapeutic agent to an external portion of the body passageway. A wide variety of therapeutic agents fall within the scope of these methods, including anti-angiogenic agents, anti-proliferative agents, anti-inflammatory agents, and antibiotics.  Also included are anti-microtubule agents such as a 'lighter d group' agent as described herein (e.g., a vanadate or vanadyl compound), or a microtubule stabilizers such as D,O discodermolide, epithilones and paclitaxel, or analogues or derivatives thereof. The therapeutic agents may further comprise a polymer such as poly(ethylene-vinyl acetate), copolymers of lactic acid and glycolic acid, poly (caprolactone), poly (lactic acid), copolymers of poly (lactic acid) and poly (caprolactone), gelatin, hyaluronic acid, collagen matrixes, and albumen.  Other carriers (e.g., liposomes) may likewise be utilized to contain and/or deliver one or more therapeutic agents.
Patent NZ-506887-A (NZ)
Title: Flow cytometer analysis of cells and body fluids for fertility testing
Inventor: SHAI SHAFRIRA
IPC: G01N33/569
Filed: 1999-03-16
Abstract: A method of determining a fraction, number or concentration of mature versus immature sperm cells in a sample containing sperm cells and white blood cells, comprising: Labeling the white blood cells in the sample with a detectable label; For each cell in at least a portion of the sample, determining whether said cell is labeled or non-labeled and whether said cell is large or small; Determining a fraction, number or concentration of large and non-labeled cells and a fraction, number or concentration of small and non-labeled cells in the sample, or portion thereof; and Based on said fraction, number or concentration or large non- labeled cells to small non-labeled cells, determining a fraction number or concentration of mature versus immature sperm cells in the sample.
Patent NZ-510936-A (NZ)
Title: Cable gate
Inventor: THOMPSON IAN REGINALD
IPC: E01F13/00
Filed: 1999-10-01
Abstract: A gate for controlling passage through an opening including a first support means located in one side of the opening (2); a second support means located on the other side of the opening (3); at least one elongate member (1), having a first and a second end, extendable across the opening between the two support means; and a control means (11) for releasing the elongate member to thereby restrict passage through the opening.
Patent NZ-511857-A (NZ)
Title: Packaging for adhesive-bandage to allow one-handed application where a bottom backing sheet and release layer are removed together
Inventor: SCHROEDER MARK R
IPC: A61F13/00
Filed: 1999-11-05
Abstract: A packaged article including an adhesive-sided article (1), such as an adhesive bandage, a release paper (13) facing the adhesive side (3) thereof, and packaging top support (4) and bottom backing (9) sheets. The facing surfaces of the top support (4) and bottom backing (9) sheets peripherally surrounding the adhesive-sided article (1) have cohesive surfaces (6, 7 and 10). An adhesive strip, preferably a double-sided adhesive strip (5), attaches the non-adhesive side (2) of the adhesive-sided article (1) to the top support sheet (4). Relative strength adhesives and cohesives are employed so that the bottom sheet (9) and top sheet (4) are first separated to leave the top sheet (4) and adhesive-sided article (1) together. The top sheet (4) is used as an applicator for placing the article (1) onto a target surface (20), such as a patient's skin. The cohesive surface (6, 7) of the top sheet (4) surrounding the article (1) does not adhere to the target surface (20). At the time, however, the top sheet "pops up" from the article (1) now adhered in place. The top sheet (4) is then removed by breaking the bond of the adhesive strip (5). All of this is conveniently done with one hand. A method of making the package and a convenient assemblage of packages similar to a matchbook assemblage (17) is also included.
Patent NZ-512593-A (NZ)
Title: Liquid container with fluid retaining portion
Inventor: MAJEWSKI RICHARD HENRY S
IPC: B65D1/04
Filed: 1999-12-17
Abstract: A container for storing and dispensing fluid including a body portion, a first neck portion joined to the body portion, and an outlet port in the neck portion for expelling fluid, wherein the body portion further includes a fluid retaining portion adapted to capture and store the fluid. This allows for more rapid dispensing of high viscosity liquids when the container is almost empty.
Patent NZ-517218-A (NZ)
Title: Treatment of conjunctivitis with a medicament comprising a "histacalcin" protein derived from a blood feeding ectoparasite
Inventor: NUTTALL PATRICIA ANNE
IPC: A61P29/00
Filed: 2000-08-24
Abstract: It has been discovered that various proteins isolated from ticks are effective in the treatment of conjunctivitis. These proteins, such as histacalin proteins MS-HBP1, FS-HBP1, FS-HBP2 or D.RET6 protein, may be applied topically to an affected area and are effective to ameliorate the symptoms of this condition.
Patent NZ-520843-A (NZ)
Title: Adhesive composition based on a formaldehyde-containing aminoplast resin, with increased cure rate
Inventor: VAN DER WAALS Adriaan Cornelis
IPC: C08G12/26
Filed: 2001-02-05
Abstract: An adhesive composition with an increased cure rate, containing 1-50%wt of free formaldehyde-like compound (a compound that can react as formaldehyde) relative to the total formaldehyde added during the adhesive preparation.  Also disclosed is a method of preparation of said adhesive, whereby an amino compound is reacted with a formaldehyde-like compound to form a resin that is then converted into the aminoplast adhesive by addition of a formaldehyde-like compound and a catalyst until an F/(NH2)2 ratio of 0.8-1.6 is achieved.
Patent NZ-525888-A (NZ)
Title: RNA interference mediating small RNA molecules
Inventor: TUSCHL THOMAS
IPC: C12N15/113
Filed: 2001-11-29
Abstract: An isolated double-stranded RNA molecule is described wherein each RNA strand has a length from about 19-25 nucleotides wherein at least one strand has a 3Æ- overhang from 1 to 5 nucleotides and the RNA molecule has sufficient identity to a nucleic acid target molecule and is capable of target-specific nucleic acid modification. The molecule can be used for mediating target-specific nucleic acid modification in a cell, for determining the function of genes and in pharmaceutical compositions.
Patent NZ-526982-A (NZ)
Title: A process for preparing (branched-alkyl) arylsulphonates and a (branched-alkyl) arylsulphonate composition
Inventor: AYOUB PAUL MARIE
IPC: C10G45/00
Filed: 2002-02-15
Abstract: A process for preparing branched alkyl aromatic hydrocarbons, which process comprises contacting branched olefins with an aromatic hydrocarbon under alkylating conditions, which branched olefins have been obtained by a process which comprises dehydrogenating an isoparaffinic composition comprising 0.5% or less quaternary aliphatic carbon atoms over a suitable catalyst, which isoparaffinic composition has been obtained by hydrocracking and hydroisomerisation of a paraffinic wax and which isoparaffinic composition comprises paraffins having a carbon number in the range of from 7 to 35, of which paraffins at least a portion of the molecules is branched, the average number of branches per paraffin molecule being 0.5 to 2.5 and the branching comprising methyl and optionally ethyl branches, said branched olefins comprising 0.5% or less quaternary aliphatic hydrocarbons, wherein the paraffinic wax is obtained in a Fischer Tropsch synthesis.
Patent NZ-531967-A (NZ)
Title: Ribavirin syrup formulations
Inventor: HEIMBECHER SUSAN K
IPC: A61P31/14
Filed: 2002-10-31
Abstract: Disclosed herein is a liquid formulation comprising ribavirin, a buffering system, wherein the pH of the liquid formulation is in the range of about 4.8 to about 5.3, at least one pharmaceutical acceptable sweetening agent, and at least one pharmaceutical acceptable viscosity increasing agent. This liquid formulation comprising ribavirin has a longer shelf life and improved taste.
Patent NZ-532458-A (NZ)
Title: Polysaccharide extraction
Inventor: GAO YI HUAI
Filed: 2004-04-20
Abstract: Disclosed is a method of extracting polysaccharides from a fungal polysaccharide source comprising the steps of: a) selecting a fungal polysaccharide source; b) extracting water soluble neutral polysaccharide (WSNP) from the source; c) separating the residue from the extraction process; and d) extracting acid soluble alkaline polysaccharide (ASAP) from the residue wherein either or both of the steps of extracting the WSNP and extracting the ASAP is/are performed by circulatory siphonic extraction. Further disclosed is a polysaccharide prepared according to the method of the invention.
Patent NZ-532939-A (NZ)
Title: A method of producing multiple non-human mammalian embryos having predetermined sex
Inventor: SEIDEL GEORGE E
IPC: C12N15/873
Filed: 1998-12-31
Abstract: Described is a method of producing multiple embryos from a female non-human mammal comprising: a) creating superovulation in the non-human mammal to create at least two eggs comprising the step of using an ovulatory pharmaceutical to cause multiple eggs to be produced, wherein the ovulatory pharmaceutical is injected in half day increments between any of days 2 and 18 of the oestrus cycle; b) determining the sex of a sperm cell of a non-human mammal; c) sorting according to sex of the sperm cells; d) inserting the sorted sperm cells into a uterus of a female non-human mammal after the onset of oestrus; and e) fertilising a plurality of eggs in the uterus to produce multiple embryos having predetermined sex.
Patent NZ-536177-A (NZ)
Title: Computer assisted remotely controlled infusion therapy system
Inventor: BUI TUAN
IPC: G06F19/00
Filed: 2003-04-28
Abstract: A system and method for assisting in verifying that the right medication is efficiently provided to the right patient, in the right dose, at the right time, and via the right route is employed for administering an infusion order (702) including a first administration, a medication, and a flow rate. The system includes first, second, and third computers. The first computer receives data identifying the order (702), the second computer provides instructions for preparing the first administration and provides a first schedule for preparation of additional administrations if additional administrations are included in the order, and the third computer provides instructions for the first administration and provides an initiation signal to the infusion machine indicating the initiation of the first administration to the patient. The third computer also provides a flow rate modification signal. The modification signal causes the system to determine whether to generate a second schedule which the second computer provides if required.
Patent NZ-539166-A (NZ)
Title: A controlled release device comprising antibiotic microspheres for treatment of infections and osteomyelitis
Inventor: CLYBURN TERRY A
IPC: A61K9/26
Filed: 2003-09-05
Abstract: A controlled release device for implantation, injection, or otherwise being placed totally or partially within the body capable of near-linear release of an antibiotic for a predetermined period of time for the treatment and prevention of infections involving the body is disclosed, which comprises: biodegradable microspheres formed of from about 85% to about 99% by weight of polylactic-co-glycolic acid (PLGA) in a ratio of 50% lactic to 50% glycolic acid; from about 0% to about 5% by weight of polyethylene glycol (PEG); and an effective amount of an antibiotic agent sufficient to produce bactericidal levels in body tissues; wherein the microspheres are of a size sufficient to not inhibit tissue regeneration, are capable of remaining at a site of treatment, and are capable of exhibiting near-linear delivery of said antibiotic agent for at least 4 weeks at levels exceeding the minimum inhibitory concentration (MIC) for organisms commonly found to be the cause of infections.
Patent NZ-542611-A (NZ)
Title: Method and device for labelling an item within a cluster, such as a banana in a bunch
Inventor: NORRIS HOWARD
Filed: 2005-09-23
Abstract: A method and device for labelling an item within an item cluster involves a signal source for sending a signal to the cluster, a signal receiver for receiving signals reflected off the cluster and a labeller which positions a label on individual items in the cluster in accordance with data analysed from the signal receiver.
Patent NZ-543939-A (NZ)
Inventor: KWOK PHILIP RODNEY
IPC: A61M16/06
Filed: 2000-02-11
Abstract: A forehead support 10 for a respiratory mask includes a joining member 14 to be secured to the mask 16 and a frame 12 adjustably mountable to the joining member and configured to move about an axis 30 that is substantially transverse of the joining member and generally parallel to the face of the forehead of a user when the mask is worn. The frame is adjustable between at least two positions and is lockable in each of those positions.
Patent NZ-547590-A (NZ)
Title: Solar tiles which form an overlapping relationship with conventional tiles
Inventor: DAVIES DANIEL GOWER
IPC: F24J2/04
Filed: 2004-10-29
Abstract: A set of tiles comprising a conventional roof tile, at least one thermal solar tile, and at least one photovoltaic tile is disclosed. The at least one solar thermal tile 1 has a chassis 6 on which is mounted a transparent portion 2 for permitting the entry of sunlight into a heating space. At least one protrusion 16, 18 on at least one edge of the chassis is configured to form an overlapping relationship 8 with an adjacent tile. The at least one solar thermal tile and the at least one photovoltaic tile have a length substantially equal to the length of the conventional roof tile 50 to 59 and a width substantially equal to multiple widths of the conventional roof tile. The at least one photovoltaic tile has a chassis that is substantially similar in external appearance to that of the at least at least one solar thermal tile with a photovoltaic material being mounted in substantially the same position as the transparent portion on the solar thermal tile chassis.
Patent NZ-548864-A (NZ)
Title: New cyrstalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
Inventor: COQUEREL GERARD
Filed: 2006-08-01
Abstract: Crystalline form V of agomelatine (N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide) is disclosed, wherein the crystalline form V of agomelatine has powder X-ray diffraction diagram, measured using a diffractometer (copper anticathode) and expressed in terms of inter-planar distance d (8.979-3.239 A[deg]), Bragg's angle 2 theta (9.84-27.51 degrees), intensity and relative intensity (expressed as a percentage with respect to the most intense ray). A process for the preparation of the crystalline form V of agomelatine is disclosed, wherein agomelatine is subjected to high energy mechanical grinding. Another process for the preparation of the crystalline form V of agomelatine is also disclosed, wherein agomelatine is heated until completely melted, then immediately placed at room temperature and simultaneously a small quantity of crystalline form V of agomelatine freshly prepared is added, and the mixture is cooled until crystallisation is complete. A pharmaceutical composition comprising as active ingredient an effective amount of crystalline form V of agomelatine is suitable for treating sleep disorders, stress, anxiety, seasonal affective disorders or severe depression, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory loss, Alzheimer's disease, cerebral circulation disorders, and also in sexual dysfunction, as ovulation inhibitors, immunomodulators and cancers.
Patent NZ-549912-A (NZ)
Title: Battery Door
Inventor: PUDNEY ARAN
Filed: 2006-09-14
Abstract: An earcup assembly (11) for a headset (10) comprising a housing having a first side adapted to engage the head of a user when in use and a second side opposite thereto. A recess provided in the second side of the housing receives and stores a battery. A battery door (14) is arranged to slidably engage the second side of the housing such that the battery door may be moved between a first, open position in which the recess is accessible to a user and a second, closed position in which the recess is covered by the battery door. Preferably, the earcup assembly includes active noise reduction circuitry. One or a pair of such earcup assemblies may be arranged to form a headset, wherein the assemblies are coupled to a headband (12) via yokes (13).
Patent NZ-555670-A (NZ)
Title: Method for the production of oxazoles by condensing aromatic aldehyde with alpha-ketoximes to N-oxides and then reacting the same with activated acid derivatives
Inventor: HOLLA WOLFGANG
IPC: A61K31/41
Filed: 2005-12-01
Abstract: Disclosed is a process for preparing compounds of formula IV which comprises converting the aromatic aldehydes of formula I using alpha-ketoximes of formula II (condensation) to the N-oxides of formula III which is reacted with an acid derivative to give a halomethyloxazole of formula IV.
Patent NZ-563404-A (NZ)
Title: Highly aerated confection
Inventor: HAEDELT JOSEFIN
IPC: A23G1/52
Filed: 2006-05-19
Abstract: The disclosure related to a highly aerated fat based confectionery material with a continuous fat phase wherein the density of the material is below 0.2 g/cm3 and at least equal to 0.1 g/cm3 and which maintains its shape and can be moulded. Also disclosed is a method for producing this material.
Patent NZ-565122-A (NZ)
Title: Isolation of the T-complex distorters and applications thereof for producing transgenic non human animals which a non-Mendelian transmission ratio of a genetic trait
Inventor: HERRMANN BERNHARD
IPC: A01K67/027
Filed: 2006-08-11
Abstract: Disclosed is a method for producing a transgenic non-human male animal , preferably a mammal, fish , bird or insect, wherein the transgene confers a change in the transmission ratio of a genetic trait to the offspring of said non-human male animal, preferably mammal, fish , bird or insect to a non-Mendelian ratio, said method comprising introducing (a) a first nucleic acid molecule encoding the murine t-complex responder Tcr into a chromosome of a non-human germ cell, fertilized egg cell, embryonic cell or a cell derived therefrom, of the same species as the transgenic male to be prepared, said chromosome containing or conferring said genetic trait, thereby linking on said chromosome said murine t-complex responder Tcr to the genetic trait; and (b) at least one second nucleic acid molecule encoding a regulator of the Rho pathway with a Distorter function into a chromosome of a nonhuman germ cell, fertilized egg cell, embryonic cell or a cell derived of the same species as the transgenic male to be prepared, wherein said regulator of the Rho pathway with a Distorter function is a factor involved in G protein signaling, wherein said first nucleic acid molecule encoding the murine t-complex responder Tcr and said at least one second nucleic acid molecule encoding a regulator of the Rho pathway with a Distorter function are introduced into the same or different chromosomes. Further disclosed are non human male or female mammals, fish, birds or insects which are transgenic for the nucleic acid molecules encoding expression product with a Responder and Distorter function and methods of detection of said nucleic acids.
Patent NZ-568273-A (NZ)
Title: Transdermal therapeutic system
Inventor: GARGIULO PAUL M
IPC: A61K9/70
Filed: 2006-10-10
Abstract: A Transdermal Therapeutic System (TTS) is disclosed, which comprises: (a) a backing layer; (b) a reservoir layer comprising rivastigmine in free base form or pharmaceutically acceptable salt form as the pharmaceutically active ingredient and one or more polymers; (c) an adhesive layer comprising a silicone polymer and a tackifier, wherein the tackifier is silicone oil; wherein the active ingredient has a maximum plasma concentration of about 1 to 30 ng/ml from a mean of about 2 to 16 hours. The disclosed Transdermal Therapeutic System is suitable as a medicament for the prevention, treatment or delay of progression of Alzheimer's disease, dementia associated with Parkinson`s disease, or symptoms of traumatic brain injury.
Patent NZ-573991-A (NZ)
Title: Pressure chamber for a compressible fluid powered device with restricted fluid channels across a movable divider
Inventor: HAMILTON HAMISH WILLIAM
IPC: G05D16/00
Filed: 2010-03-23
Abstract: A compressible fluid powered device is disclosed, particularly with regard to pneumatic tools. Portable pressure sources have been developed by which a vessel containing a pressurised fluid such as carbon dioxide may be connected via a regulator to a tool traditionally powered by an air compressor. Because these tools have been designed for a pneumatic set up where the supply of compressed air or gas is effectively unlimited, the energy transfer is relatively inefficient. To overcome this, a dose chamber (2), where the dose of fluid to drive the tool is metered, is divided into a primary space (6) and a secondary space (7) by a moveable divider (5), where movement of the divider expanding one space at the expense of the other. An inlet (3) supplies pressurised fluid to the primary space of the dose chamber and an outlet (4) releases the pressurised fluid from the primary space of the dose chamber. At least one flow pathway (10a, 10b, 10c) connects one space to the other, which collectively allow gas to flow in both directions past the divider and allow pressure to equalise across the divider, the flow pathway being more limited than the outlet. Although the dividing flow pathways allow the pressure in the primary space and secondary space to equalise, the flow rate is significantly lower than that which may be achieved through the outlet. Accordingly, when a rapid cycle of releasing the fluid through outlet and then closing outlet is repeated, the flow of gas across the divider is restricted and there is insufficient time for the pressure across the divider to equalise. Adjusting the location of the divider adjusts the volume of the high pressure charge for the tool as only a small amount of the high pressure fluid in the secondary chamber is able to escape while the outlet is open. This means the power of the tool is adjustable resulting in a smaller amount of fluid being used per operating cycle, reducing the degree to which the temperature of the operating mechanism will be lowered. From this, a greater number of repetitions may be achieved before freezing issues arise - increasing the usability of the tool.